Insight Molecular Diagnostics Inc. (IMDX) has a negative trailing P/E of -1.8, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -54.21%.
Criteria proven by this page:
Overall SharesGrow Score: 40/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -16.7 | -13.93 | 18.96 | 0.00 | - |
| 2017 | -7.2 | -0.14 | 31.89 | 0.00 | - |
| 2018 | -3.3 | 0.09 | 15.26 | 0.00 | 0.18% |
| 2019 | -5.2 | -1.10 | 3.74 | 0.00 | - |
| 2020 | -5.2 | -1.06 | 4.67 | 128.69 | - |
| 2021 | -3.0 | -0.05 | 2.96 | 87.79 | - |
| 2022 | -0.5 | -0.01 | 0.90 | 37.13 | - |
| 2023 | -0.7 | 0.01 | 0.93 | 12.73 | - |
| 2024 | -0.5 | -0.02 | -2.53 | 16.54 | - |
| 2025 | -4.6 | 0.07 | -7.26 | 56.37 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-8.42 | $0.00 | $-11.17M | - |
| 2017 | $-12.83 | $0.00 | $-19.38M | - |
| 2018 | $-8.32 | $0.00 | $-15.75M | - |
| 2019 | $-8.71 | $0.00 | $-22.33M | - |
| 2020 | $-9.14 | $1.22M | $-29.93M | -2461.5% |
| 2021 | $-14.42 | $7.73M | $-64.1M | -829.5% |
| 2022 | $-13.26 | $958K | $-73.44M | -7666% |
| 2023 | $-3.75 | $1.5M | $-27.78M | -1848.4% |
| 2024 | $-4.66 | $1.88M | $-60.66M | -3225% |
| 2025 | $-1.65 | $4.06M | $-50.22M | -1238.5% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.90 | $-1.24 – $-0.25 | $2.68M | $733.86K – $5.19M | 4 |
| 2027 | $-0.74 | $-0.82 – $-0.68 | $8.24M | $1.31M – $12M | 4 |
